JP2013544244A5 - - Google Patents

Download PDF

Info

Publication number
JP2013544244A5
JP2013544244A5 JP2013539093A JP2013539093A JP2013544244A5 JP 2013544244 A5 JP2013544244 A5 JP 2013544244A5 JP 2013539093 A JP2013539093 A JP 2013539093A JP 2013539093 A JP2013539093 A JP 2013539093A JP 2013544244 A5 JP2013544244 A5 JP 2013544244A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
interleukin
inflammation
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2013539093A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013544244A (ja
Filing date
Publication date
Priority claimed from CN201010551433.8A external-priority patent/CN102462837B/zh
Application filed filed Critical
Publication of JP2013544244A publication Critical patent/JP2013544244A/ja
Publication of JP2013544244A5 publication Critical patent/JP2013544244A5/ja
Pending legal-status Critical Current

Links

JP2013539093A 2010-11-19 2011-11-09 抗炎症組成物 Pending JP2013544244A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201010551433.8 2010-11-19
CN201010551433.8A CN102462837B (zh) 2010-11-19 2010-11-19 抗炎组合物
PCT/AU2011/001446 WO2012065212A1 (en) 2010-11-19 2011-11-09 Anti-inflammatory compositions

Publications (2)

Publication Number Publication Date
JP2013544244A JP2013544244A (ja) 2013-12-12
JP2013544244A5 true JP2013544244A5 (enExample) 2014-12-25

Family

ID=46067145

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013539093A Pending JP2013544244A (ja) 2010-11-19 2011-11-09 抗炎症組成物

Country Status (12)

Country Link
US (1) US9289493B2 (enExample)
EP (1) EP2640411B1 (enExample)
JP (1) JP2013544244A (enExample)
KR (1) KR101989201B1 (enExample)
CN (1) CN102462837B (enExample)
AU (1) AU2011331901B2 (enExample)
CA (1) CA2817996C (enExample)
DK (1) DK2640411T3 (enExample)
MX (1) MX348794B (enExample)
MY (1) MY174797A (enExample)
RU (1) RU2627451C9 (enExample)
WO (1) WO2012065212A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112013023151A2 (pt) 2011-03-11 2020-09-15 Assistance Publique - Hôpitaux De Paris interleucina-2 para uso no tratamento de desordem auto-imune, !muno-relacionada ou inflamatória e método para determinar se um regime ou dose de il-2 tem de ser modificado
DK3443979T3 (da) 2011-03-11 2020-08-24 Assist Publique - Hôpitaux De Paris Il-2-doseringsplan til behandling af systemisk lupus erythematosus
NL2009794C2 (nl) 2012-11-13 2014-05-14 Hevorma B V Groei-inrichting voor gewas, gebruik van een dergelijke inrichting, en een reeks groei-inrichtingen.
EP3482766B1 (en) 2014-08-11 2020-05-20 Delinia, Inc. Modified il-2 variants that selectively activate regulatory t cells for the treatment of autoimmune diseases
US20170204154A1 (en) 2016-01-20 2017-07-20 Delinia, Inc. Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
WO2018051183A1 (en) * 2016-09-15 2018-03-22 Skintech Life Science Limited Sublingual or buccal administration of dim for treatment of skin diseases
CN110167957A (zh) 2016-11-08 2019-08-23 德里尼亚公司 用于治疗自身免疫疾病的il-2变体
PH12022550165A1 (en) 2019-07-26 2023-05-08 Visterra Inc Interleukin-2 agents and uses thereof
PE20221759A1 (es) 2020-03-31 2022-11-11 Hanmi Pharm Ind Co Ltd Nuevos analogos de il-2 inmunoestimuladores
EP4255466A1 (en) 2020-12-04 2023-10-11 Visterra, Inc. Methods of using interleukin-2 agents

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4925673A (en) * 1986-08-18 1990-05-15 Clinical Technologies Associates, Inc. Delivery systems for pharmacological agents encapsulated with proteinoids
EP0462305B1 (de) * 1990-06-21 1994-11-02 Huland, Edith, Dr. Dr. Verwendung zytokinhaltiger Aerosole und zytokinhaltige Aerosole selbst
US6509313B1 (en) * 1996-02-28 2003-01-21 Cornell Research Foundation, Inc. Stimulation of immune response with low doses of cytokines
US7361331B2 (en) * 1996-10-18 2008-04-22 Her Majesty The Queen In Right Of Canada, As Represented By The Minister Of Agriculture And Agri-Food Plant bioreactors
JP4023863B2 (ja) 1997-03-13 2007-12-19 アプライド・リサーチ・システムズ・エイアールエス・ホールディング・ナムローゼ・フェンノートシャップ Il−6を含む血清尿酸値低下剤
FR2769505B1 (fr) * 1997-10-10 2000-06-30 Michael Gerard Tovey Compositions de cytokines a administrer a la muqueuse buccale, et leurs utilisations
US6974590B2 (en) 1998-03-27 2005-12-13 Cima Labs Inc. Sublingual buccal effervescent
JP2002532556A (ja) * 1998-12-22 2002-10-02 シェリング・コーポレーション C型肝炎ウイルス感染のインターロイキン−10での処置
IL148300A0 (en) 1999-09-09 2002-09-12 Schering Corp Mammalian cytokines; related reagents and methods
AUPR272901A0 (en) 2001-01-25 2001-02-22 Gainful Plan Limited Method of preparing biological materials and preparations produced using same
CA2498931A1 (en) 2002-09-16 2004-03-25 Wyeth Delayed release formulations for oral administration of a polypeptide therapeutic agent and methods of using same
GB0501540D0 (en) * 2005-01-25 2005-03-02 Univ Leeds Controlled production and delivery of biologically active agents by gut bacteria
WO2008109953A1 (en) 2007-03-14 2008-09-18 Sai Ying Ko Method for treating cancer via the mucosal administration of interleukin
CN102174111B (zh) * 2011-01-25 2013-01-09 江苏省弗泰生物科技有限公司 人白介素2-Fc融合蛋白及其用途

Similar Documents

Publication Publication Date Title
JP2013544244A5 (enExample)
RU2013127793A (ru) Противовоспалительные композиции
JP2016523862A5 (enExample)
EA201290171A1 (ru) Вводимые перорально кортикостероидные композиции
JP2015129189A5 (enExample)
JP2014526503A5 (enExample)
EA200800881A1 (ru) Лекарственная форма пирфенидона в виде капсул с фармацевтически приемлемыми эксципиентами
JP2013510123A5 (enExample)
JP2016517888A5 (enExample)
CN103429236A (zh) 治疗高尿酸血症和与高尿酸血症相关的代谢性病症的方法和组合物
Lee et al. Tramadol 37.5-mg/acetaminophen 325-mg combination tablets added to regular therapy for rheumatoid arthritis pain: a 1-week, randomized, double-blind, placebo-controlled trial
AR095372A1 (es) Terapia de inducción con rituximab seguida por una terapia con acetato de glatiramer
JP2018505158A5 (enExample)
JP2014523906A5 (enExample)
JP2009544690A5 (enExample)
JP2011157375A5 (enExample)
MA38169A1 (fr) Ciclésonide pour le traitement d'une maladie des voies respiratoires chez les chevaux
JP2019527714A5 (enExample)
JP2009502805A5 (enExample)
JP2008516909A5 (enExample)
JP2008533079A5 (enExample)
CN103040805A (zh) 辛夷脂素的医药用途
Weng et al. The common link between sleep apnea syndrome and osteoarthritis: a literature review
CN111315370A (zh) 一种具有抗炎症性肠病作用的药物及其制备方法和应用
Black et al. Interventions to reduce the frequency of exacerbations of chronic obstructive pulmonary disease